Healthcare / Diagnostics & ResearchShanghai
$6.59
-0.16 (-2.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $24.0M · quality 49.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.6B
P/E
73.2x
↑EV/EBITDA
24.5x
↑ROE
3.1%
↑Gross Margin
66.5%
↑Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-10.6%
FCF CAGR
-41.4%
FCF margin
7.2%
FCF / Net income
0.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $332.7M · net income $43.9M · FCF $24.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $332.7M | $332.7M | $436.3M | $445.3M | $465.3M |
| Net Income | $43.9M | $43.9M | $127.1M | $147.4M | $152.6M |
| EBITDA | $112.7M | $112.7M | $196.9M | $215.9M | $229.1M |
| EPS | 0.11 | 0.11 | 0.32 | 0.37 | 0.38 |
| Gross Margin | 66.5% | 66.5% | 74.7% | 75.4% | 74.4% |
| Operating Margin | 14.0% | 14.0% | 28.8% | 33.2% | 32.0% |
| Net Margin | 13.2% | 13.2% | 29.1% | 33.1% | 32.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.16 | 0.16 | 0.18 | 0.17 | 0.01 |
| Current Ratio | 4.77 | 4.77 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $24.0M | $24.0M | $60.5M | $-128.3M | $119.3M |
| Returns | |||||
| ROE | 3.1% | 3.1% | 9.0% | 10.6% | 11.1% |
| Valuation | |||||
| P/E | 73.22 | 73.22 | 20.16 | 27.78 | 26.74 |
| EV/EBITDA | 24.45 | 24.45 | 12.25 | 17.98 | 16.37 |
| P/B | 1.86 | 1.86 | 1.81 | 2.95 | 2.96 |
| Growth & Yield | |||||
| Revenue Growth | -23.7% | -23.7% | -2.0% | -4.3% | — |
| EPS Growth | -65.6% | -65.6% | -13.5% | -2.6% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
74.5%
EPS terminal req.
$0.58
Spread vs growth
-140.2%
5Y implied EPS CAGR
45.1%
EPS terminal req.
$0.71
Spread vs growth
-110.7%
10Y implied EPS CAGR
26.3%
EPS terminal req.
$1.14
Spread vs growth
-92.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.3%
Start / end P/E
23.2x → 59.9x
EPS bridge
0.32 → 0.11
Residual
-103.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.